AZD1222: A COVID-19 Vaccine Study

Official Title: D8110C00001: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (A COVID-19 Vaccine Study)


SARS-CoV-2 is a new coronavirus that first appeared in China in November 2019. It was associated with cases of pneumonia. This virus causes the illness that is now called COVID-19. People with COVID-19 may have symptoms ranging from mild symptoms or severe illness, even death. Older adults and people with medical conditions like heart or lung disease or diabetes seem to be at higher risk for developing complications from COVID-19 illness. As a response to the ongoing pandemic, AstraZeneca is developing an investigational vaccine, also known as AZD1222, for the prevention of COVID-19. This study is being done to see if a vaccine that is being developed to prevent people from getting sick with COVID-19 is safe and effective and also to see how well it is tolerated.

Eligibility criteria:

- 18 years of age or older
- In good or stable health (you may have an underlying medical condition and still take part, if your disease is stable)
- Have an increased risk of getting COVID-19
- Do not have a previously confirmed diagnosis of COVID-19

Contact Information

Kathy Watson